JoVE Logo

S'identifier

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces the same desired effect at a lower dose. It is noteworthy that both drugs exhibit similar maximum effect or Emax values, implying that they possess equal efficacy. Efficacy depends on the number of drug–receptor complexes formed and the extent of receptor activation. Maximal efficacy is achieved when all receptors are occupied, rendering further increases in drug concentration incapable of eliciting additional responses. Full agonists have high efficacy, as they activate receptors entirely and elicit a complete response. The efficacy of partial agonists is lower, as they activate receptors to a lesser extent. Antagonists, in contrast, exhibit zero efficacy by not activating the receptors. Instead, they act as blockers and either reduce the number of available receptors for agonist binding or induce conformational changes that prevent effective agonist binding. Overall, these factors play a crucial role in determining the efficacy and potency of drugs, which, in turn, can determine their usefulness in treating various medical conditions.

Tags

Dose response RelationshipPotencyEfficacyEC50 ValuesCandesartanIrbesartanMaximum EffectEmax ValuesDrug receptor ComplexesReceptor ActivationFull AgonistsPartial AgonistsAntagonistsDrug ConcentrationMedical Treatment

Du chapitre 4:

article

Now Playing

4.9 : Dose-Response Relationship: Potency and Efficacy

Pharmacodynamics

4.0K Vues

article

4.1 : Principes de l’action des médicaments

Pharmacodynamics

5.6K Vues

article

4.2 : Cibles d’action médicamenteuse : Vue d’ensemble

Pharmacodynamics

5.9K Vues

article

4.3 : Transduction du signal : Vue d’ensemble

Pharmacodynamics

8.1K Vues

article

4.4 : Mécanisme du transducteur : récepteurs couplés aux protéines G

Pharmacodynamics

1.7K Vues

article

4.5 : Récepteur de canal ionique ligand-dépendant : mécanisme de déclenchement

Pharmacodynamics

2.0K Vues

article

4.6 : Mécanisme du transducteur : récepteurs enzymatiques

Pharmacodynamics

2.3K Vues

article

4.7 : Mécanisme du transducteur : récepteurs nucléaires

Pharmacodynamics

1.2K Vues

article

4.8 : Relation dose-réponse : aperçu

Pharmacodynamics

2.8K Vues

article

4.10 : Relation dose-réponse : sélectivité et spécificité

Pharmacodynamics

6.2K Vues

article

4.11 : Indice thérapeutique

Pharmacodynamics

4.0K Vues

article

4.12 : Interaction médicament-récepteur : agoniste

Pharmacodynamics

2.3K Vues

article

4.13 : Interaction médicament-récepteur : antagoniste

Pharmacodynamics

2.5K Vues

article

4.14 : Effets combinés des drogues : antagonisme

Pharmacodynamics

8.1K Vues

article

4.15 : Effets combinés des médicaments : synergie

Pharmacodynamics

3.6K Vues

See More

JoVE Logo

Confidentialité

Conditions d'utilisation

Politiques

Recherche

Enseignement

À PROPOS DE JoVE

Copyright © 2025 MyJoVE Corporation. Tous droits réservés.